股票代码：600965 股票简称：福成股份 公告编号：2025-024 河北福成五丰食品股份有限公司 2025 年半年度食品制造业主要经营数据公告 | | | 报告期内主营业务按产品分项分 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 产品分项 | 营业收入 | 营业成本 | 毛利率 | 营业收入 | 营业成本 | 毛利率比 | | | | | （%） | 比上年增 | 比上年增 | 上年增减 | | | | | | 减（%） | 减（%） | （%） | | 牛肉 | 138,913,404.14 | 120,734,008.28 | 13.09 | 76.67 | 93.48 | -7.55 | | 羊肉 | 7,205,991.77 | 5,313,465.96 | 26.26 | 11.30 | 11.40 | -0.07 | | 肉制品 | 64,962,037.16 | 56,475,568.58 | 13.06 | -23.58 | -20.39 | -3.49 | | 乳制品 | 44,603,928.66 | 38,984,6 ...

Core Viewpoint - Oriental Selection reported a significant decline in net revenue and profit for the fiscal year 2025, but showed signs of recovery in its core business after adjusting for one-time expenses related to the "With Huixing" sale [1] Group 1: Financial Performance - For the fiscal year 2025, the total net revenue from continuing operations was 4.4 billion yuan, a year-on-year decrease of 32.7% [1] - The net profit from continuing operations was 6.19 million yuan, down 97.5% year-on-year, but showed a recovery from losses in the first half of the fiscal year [1] - Excluding one-time expenses, the net profit from continuing operations was 140 million yuan, representing a year-on-year growth of 30% [1] Group 2: Business Strategy and Growth - The company's self-operated product expansion strategy has taken shape, becoming a core growth engine, with self-operated product GMV reaching approximately 3.81 billion yuan, accounting for 43.8% of total GMV [2] - The self-operated product revenue was about 3.5 billion yuan, making up 80% of total revenue, with a significant increase in the number of self-operated products launched [2] - The gross margin improved from 25.9% in fiscal year 2024 to 32.0% in fiscal year 2025, an increase of 6 percentage points [2] Group 3: APP Development and Membership Growth - The company's self-owned APP channel achieved steady growth, with APP revenue of approximately 1.1 billion yuan, a year-on-year increase of 22%, accounting for 25% of total revenue [3] - The GMV from the APP channel increased from 16.3% in fiscal year 2024 to 28.8% in fiscal year 2025 [3] - The number of paid APP members reached 264,000, a year-on-year growth of 33%, with high user satisfaction at 98.7% [3]

Core Viewpoint - The company, China Resources Sanjiu, is facing significant challenges as its traditional revenue streams are stagnating, new business ventures are not performing well, and it is struggling to keep pace with competitors in a tightening regulatory environment [2][3]. Business Performance - In 2024, the company reported total sales of 276 billion yuan, but the growth rate is declining, indicating potential risks [3]. - The company's flagship products, which account for 45% of sales (approximately 125 billion yuan), have seen a decrease in growth from nearly 20% in 2023 to 14% in 2024, suggesting they are nearing market saturation [4]. - New products launched in 2024, such as vitamin D drops and probiotics, contributed less than 3% to revenue, indicating poor market reception [5]. Prescription and Over-the-Counter Drugs - The prescription drug segment, which was previously a strong revenue generator, has been negatively impacted by national price cuts, resulting in a gross margin decline of 4.6 percentage points in 2024 [5][10]. - The company’s retail business generated 33.7 billion yuan in 2024, but with a low gross margin of only 13.4%, highlighting inefficiencies in physical store operations [6]. Financial Metrics - In Q1 2025, the company reported revenue of 68.54 billion yuan, a year-on-year decline of 6.04%, and a net profit of 12.7 billion yuan, down 6.87% [8][10]. - Compared to competitors, the company is lagging, with its gross margin at 53.28%, significantly lower than peers like Dong-E E-Jiao at 73.62% [9][10]. Acquisition and Integration Challenges - The acquisition of Kunming Pharmaceutical Group has not yielded expected benefits, with its revenue growth at only 7.3% and a gross margin drop of 7.4 percentage points [6][11]. - The company faces high management integration costs post-acquisition, and the goodwill from acquisitions poses a risk of impairment, amounting to 51.24 billion yuan, which is 25.7% of the company's net assets [11]. Research and Development - The company has increased its R&D investment from 5.94 billion yuan in 2022 to 8.02 billion yuan in 2024, maintaining a 16.8% annual growth rate [12]. - However, the capitalized R&D ratio has dropped from 22.35% to 15.87%, indicating potential issues with project maturity and profitability [13]. - The R&D team has expanded significantly, but labor costs now account for 37.7% of R&D expenses, raising concerns about the efficiency of these investments [14].

股票代码：600965 股票简称：福成股份 公告编号：2025-015 河北福成五丰食品股份有限公司 2025 年第一季度食品制造业主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》及 《上海证券交易所上市公司自律监管指引第 3 号-第十四号食品制造》的要求， 河北福成五丰食品股份有限公司现将 2025 年第一季度食品制造业主要经营数据 披露如下： 一、食品制造业主要经营数据 1、报告期内细分产品情况 | 产品类别 | 产量（吨） | 销量（吨） | 库存量（吨） | 产量比上年 增减（%） | 销量比上年 增减（%） | 库存量比 上年增减 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | （%） | | 牛肉 | 2,952.72 | 3,103.15 | 898.24 | 197.82 | 189.51 | 45.47 | | 羊肉 | 63.09 | 63.18 ...